Key result
Circulating levels of adiponectin and leptin were significantly lower among treated hypertensives compared to newly diagnosed untreated hypertensives and healthy controls (P<0.001).
Why the study?
Are circulating levels of adiponectin, leptin, and TNF-alpha associated with hypertension and its treatment?
Cross-Sectional (n=387)
Are circulating levels of adiponectin, leptin, and TNF-alpha associated with hypertension and its treatment?
p-value: p=<0.001
Circulating adipocytokine levels are altered in hypertension and influenced by pharmacological treatment and comorbidities, complicating their clinical utility as simple biomarkers.
No takes yet. Share an insight, caveat, or question.
Lower adipocytokine levels in treated hypertension complicate biomarker interpretation; leaves open causal and prognostic roles pending longitudinal studies.
Patel et al. (2009) conducted a cross-sectional in Hypertension (n=387). Treated hypertension vs. Newly diagnosed untreated hypertensives and healthy controls was evaluated on Plasma levels of adiponectin, leptin, and tumour necrosis factor alpha (p=<0.001). Circulating levels of adiponectin and leptin were significantly lower among treated hypertensives compared to newly diagnosed untreated hypertensives and healthy controls (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: